138751-74-3

Basic information

• Product Name: 7-(1R,4R)-2,5-Diaza-bicyclo[2.2.1]hept-2-yl-1-(2,4-difluoro-phenyl)-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid
• Synonyms: 7-(1R,4R)-2,5-Diaza-bicyclo[2.2.1]hept-2-yl-1-(2,4-difluoro-phenyl)-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid
• CAS NO: 138751-74-3
• Molecular Weight: 416.359
• Mol File: 138751-74-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 7-(1R,4R)-2,5-Diaza-bicyclo[2.2.1]hept-2-yl-1-(2,4-difluoro-phenyl)-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 7-(1R,4R)-2,5-Diaza-bicyclo[2.2.1]hept-2-yl-1-(2,4-difluoro-phenyl)-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid(138751-74-3)
• EPA Substance Registry System: 7-(1R,4R)-2,5-Diaza-bicyclo[2.2.1]hept-2-yl-1-(2,4-difluoro-phenyl)-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid(138751-74-3)

Safety Data

• Hazardous Substances Data: 138751-74-3(Hazardous Substances Data)

Upstream product

• 100490-99-1 ethyl-3,1-(2,4-difluoroanilino)-2-(2,6-dichloro-5-fluoronicotinyl) acrylate 
• 100491-29-0 ethyl 7-chloro-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylate 
• 82671-06-5 2,6-dichloro-5-fluoro-3-pyridinecarboxylic acid 
• 96568-02-4 2,6-dichloro-5-fluoro-3-nicotinoyl chloride 
• 96568-05-7 2,6-dichloro-α-(ethoxymethylene)-5-fluoro-β-oxo-3-pyridinepropanoic acid ethyl ester 
• 96568-04-6 ethyl 3-(2,6-dichloro-5-fluoropyridin-3-yl)-3-oxopropanoate 
• 367-25-9 2,4-difluorophenylamine 

Relevant articles and documents

Fluoronaphthyridines as Antibacterial Agents. 4. Synthesis and Structure-Activity Relationships of 5-Substituted-6-fluoro-7-(cycloalkylamino)-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic Acids

A series of 5-substituted-6-fluoro-7-(cycloalkylamino)-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids have been prepared and tested for their in vitro and in vivo antibacterial activities.The 5-methyl group gave better in vitro activity with the 1-cyclopropyl appendage, but poorer activity with the 1-tert-butyl moiety.With the 1-(2,4-difluorophenyl) substitution, the influence of the 7-cycloalkylamino group was determinant: a (3S)-3-aminopyrrolidine was shown to enhance greatly the in vitro and in vivo activity of the 5-methyl derivative.Compound 33 (BMY 43748) was selec ted as a promising candidate for an improved therapeutic agent.